Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The Cleveland ...

Please provide your email address to receive an email when new articles are posted on . Ganaxolone was generally well tolerated and significantly reduced the frequency of seizures associated with ...

One of the most common types of genetic epilepsy, CDKL5 deficiency disorder (CDD), causes seizures and impaired development. Children are currently treated with generic antiepileptic drugs, as there ...

Discover the novel gene therapy for genetic epilepsy or CDKL5 deficiency disorder, offering a beacon of hope in children affected by this condition. CDD - CDKL5 deficiency disorder, a most common type ...

Total RNA was extracted from lymphocytes using the QIAamp RNA blood mini kit (Qiagen). RNA was converted to cDNA using a superscript first-strand synthesis system for RT-PCR (Invitrogen). PCR primers ...

Penny Howard arrived in Philadelphia last month anxious to see her daughter, Harper, again. It had been more than one year since Penny's little girl died from a rare disease called CDKL5 that marked ...

Please provide your email address to receive an email when new articles are posted on . Marinus Pharmaceuticals Inc. announced the Unites States commercial launch of Ztalmy oral suspension for the ...

The European Commission has granted marketing authorisation in the European Union (EU) for Ztalmy ® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with ...

“ZTALMY represents an important first for both Marinus and the CDD community and we are proud to make it available for patients by physician prescription,” said Christy Shafer, Chief Commercial ...

ATLANTA - UCB’s phase 3 study of fenfluramine for treating seizures associated with CDKL5 deficiency disorder (CDD) has met its primary endpoint, the biopharmaceutical company announced Monday. The ...